Results 231 to 240 of about 37,412 (255)
Some of the next articles are maybe not open access.
Dual Angiotensin II and Endothelin Receptor Antagonists
American Journal of Therapeutics, 2011Endothelin and angiotensin II are potent vasoconstrictor substances that also can exert proliferative and proinflammatory effects. Dysregulation of these systems can induce or mediate endothelial dysfunction and organ damage in systemic hypertension. Dual-acting angiotensin II and endothelin receptor blockers have been shown to reduce systemic blood ...
Chandrasekar, Palaniswamy +2 more
openaire +2 more sources
Pharmacology of the angiotensin II receptor antagonist, eprosartan
Expert Opinion on Investigational Drugs, 1998The non-peptide angiotensin II receptor antagonists represent a new class of drugs with demonstrated efficacy in the treatment of hypertension. Eprosartan is a potent, orally active AT(1) receptor antagonist which is chemically distinct from losartan and other non-peptide angiotensin II receptor antagonists.
R M, Edwards, R R, Ruffolo, D P, Brooks
openaire +2 more sources
Teratogenicity with angiotensin II receptor antagonists in pregnancy
Journal of Endocrinological Investigation, 2005Angiotensin converting enzyme (ACE) inhibitors and angiotensin II (AT-II)-receptor-antagonists have been demonstrated to cause fetotoxicity when administered to women during the second and third trimester of pregnancy. Although use of ACE inhibitors during the first trimester of pregnancy seems to be safe, with no associated teratogenicity, there is ...
E, Boix, P, Zapater, A, Picó, O, Moreno
openaire +2 more sources
Angiotensin II-receptor antagonist in the treatment of hypertension
Current Hypertension Reports, 2005Effective treatment of high blood pressure levels represents a crucial point in reducing global cardiovascular risk, and several studies have clearly demonstrated a significant reduction in cardiovascular and renal morbidity and mortality with a more intensive blood pressure-lowering treatment.
VOLPE, Massimo +2 more
openaire +3 more sources
Angiotensin II receptor antagonists.
Arzneimittel-Forschung, 1993The development of novel non-peptide compounds with high affinity for-angiotensin II (Ang II) receptors has greatly facilitated the subclassification of Ang II receptors into AT1- and AT2-receptor subtypes. Whereas PD 123177 (1-(4-amino-3-methylphenyl)methyl-5-diphenyl-acetyl-4,5,6,7-tetrahydro- 1H-imidazol [4,5-c]pyridine-6-carboxylic acid) is the ...
J C, van Meel +5 more
openaire +1 more source
Pharmacology of Nonpeptide Angiotensin II Receptor Antagonists
Annual Review of Pharmacology and Toxicology, 1992Nonpeptide angiotensin II (All) receptor antagonists are a new class of drugs whose actions as experimental tools and potential therapeutic agents result from a specific blockade of the actions of All (1-3) . All is the primary humoral mediator of the renin angiotensin system (RAS). In this well characterized system, angiotensinogen is produced by the
R D, Smith +4 more
openaire +2 more sources
Angiotensin II Receptor Antagonists: The Prototype Losartan
Annals of Pharmacotherapy, 1996Objective To describe a new class of antihypertensive agents, the angiotensin II receptor antagonists, with emphasis on the prototype losartan. Pharmacokinetic data and clinical trials are reviewed, as well as adverse reactions, drug interactions, and dosing guidelines.
Karen L Schaefer +3 more
openaire +2 more sources
Therapeutic potential of angiotensin II receptor antagonists
Expert Opinion on Investigational Drugs, 2001The circulating renin-angiotensin system plays an important role in cardiovascular homeostasis. More importantly, the local tissue renin angiotensin plays a pivotal role in cell growth and remodelling of cardiomyocytes and on the peripheral arterial vasculature.
M, White +3 more
openaire +2 more sources
Fimasartan, a novel angiotensin II receptor antagonist
Archives of Pharmacal Research, 2012Fimasartan (Kanarb®), an angiotensin II receptor antagonist with selectivity for the AT1 receptor subtype, is a pyrimidinone-related heterocyclic compound that was developed by Boryung Pharm. Co., Ltd. Among numerous synthetic derivatives, fimasartan was chosen as a new drug candidate through in vitro and in vivo screening studies.
Je Hak, Kim +4 more
openaire +2 more sources
ACE Inhibitors and Angiotensin II Receptor Antagonists
2005The biological actions of angiotensin II (ANG), the most prominent hormone of the renin-angiotensin-aldosterone system (RAAS), may promote the development of atherosclerosis in many ways. ANG aggravates hypertension, metabolic syndrome, and endothelial dysfunction, and thereby constitutes a major risk factor for cardiovascular disease. The formation of
A, Dendorfer, P, Dominiak, H, Schunkert
openaire +2 more sources